Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of adefovir dipivoxil in chronic hepatitis B
2015-004890-34Phase 3
- Sponsor
- GSK
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of adefovir dipivoxil and lamivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in serum HBV DNA level at Week 52.
02
Drugs
adefovir dipivoxillamivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2015-004890-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004890-34.